Niranjan Kanesa-Thasan - 02 Feb 2022 Form 4 Insider Report for Icosavax, Inc.

Role: Chief Medical Officer
Signature: /s/ Elizabeth Bekiroglu, Attorney-in-Fact
Issuer symbol: N/A
Transactions as of: 02 Feb 2022
Net transactions value: +$52,101
Form type: 4
Filing time: 04 Feb 2022, 17:25:18 UTC
Previous filing: 02 Aug 2021
Next filing: 14 Feb 2022
SEC: View on sec.gov

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
transaction	ICVX	Common Stock	Options Exercise	$11,596	+13,805	+8.2%	$0.8400^*	182,461	02 Feb 2022	Direct
transaction	ICVX	Common Stock	Options Exercise	$40,505	+38,947	+21%	$1.04^*	221,408	02 Feb 2022	Direct

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
transaction	ICVX	Stock Option (Right to Buy)	Options Exercise	$0	-13,805	-46%	$0.000000	16,317	02 Feb 2022	Common Stock	13,805	$0.8400	Direct	F1
transaction	ICVX	Stock Option Right to Buy)	Options Exercise	$0	-38,947	-25%	$0.000000	116,841	02 Feb 2022	Common Stock	38,947	$1.04	Direct	F2

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	25% of the shares subject to the option vested on 4/1/2021, and 1/48th of the shares subject to the option vest monthly thereafter.
F2	25% of the shares subject to the option vested on 1/14/2022, and 1/48th of the shares subject to the option vest monthly thereafter.